Targets › PRPH2
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Aug 2027.
Essential for retina photoreceptor outer segment disk morphogenesis, may also play a role with ROM1 in the maintenance of outer segment disk structure (By similarity). Required for the maintenance of retinal outer nuclear layer thickness (By similarity). (UniProt, P23942)
Open in Phaseline: the race on PRPH2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| n-Lorem Foundation | nL-PRPH2-001 Antisense oligonucleotide targeting PRPH2 | PRPH2 | Phase 1 | Retinal Dystrophy | Aug 2027 |
Retinal Dystrophy (1)
small molecule (1)
n-Lorem Foundation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.